SVASTEK, a promising Medtech startup focused on transforming respiratory and critical care, has successfully raised Rs 2 crore in seed funding. The round was led by IAN Angel Fund, a key player in early-stage investments.
The funds will be instrumental in accelerating the launch of SVASTEK’s innovative ALLTIP-enabled Non-Invasive Ventilation (NIV) mask across India. The company plans to build a distributor network to ensure widespread product availability, expand its clinical application team, and enhance brand visibility through medical conferences and targeted outreach initiatives.
Founded in 2022 by Arita Abrol, SVASTEK addresses critical gaps in the respiratory care sector with patented solutions designed for large-scale hospital use. By innovating at the intersection of technology and healthcare, SVASTEK aims to improve patient outcomes and revolutionize critical care practices.
SVASTEK’s flagship product, the ALLTIP Technology-enabled NIV mask, is set to reshape the way continuous non-invasive ventilation is administered. The mask allows for the simultaneous delivery of nutrition, enhancing clinical outcomes and reducing risks associated with malnutrition in patients requiring long-term respiratory support.
With the respiratory and critical care market in India valued at Rs 48,500 crores (approximately $5.8 billion) and growing at a CAGR of 8.3%, SVASTEK is poised to capture significant market share. The company also plans to expand its product portfolio and geographic reach, striving to become a global leader in respiratory care and making healthcare more innovative, affordable, and accessible worldwide.
